Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-136-5p
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Prognosis
Upstream regulatory factors
Not available
Downstream target
PPP2R2A
Cancer name
Non-Small Cell Lung Cancer
Cancer site
qRT-PCR,Western blot,Dual-luciferase assay
Treatment type
Chemotherapy
Drug
Anlotinib
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
8
Male patients
7
Female patients
41-80
Age range and number
Not available
PMID
Description
these findings indicated that anlotinib-resistant NSCLC cell-derived exosomal miR-136-5p confers anlotinib resistance in NSCLC cells by targeting PPP2R2A
Tissue resource
tumor tissue samples and plasma samples from non-small cell lung cancer patients
human non-small cell lung cancer cell lines A549
human non-small cell lung cancer cell lines NCI-H1975
Experiment
15
Institute
the Affiliated Lianyungang Hospital of Xuzhou Medical University
American Type Culture Collection
Country
China
United States
Continent
Asia
North Amercian
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.